FibroBiologics, Inc. (NASDAQ:FBLG) Stake Boosted by Barclays PLC

Barclays PLC lifted its stake in shares of FibroBiologics, Inc. (NASDAQ:FBLG) by 363.2% during the third quarter, Holdings Channel reports. The firm owned 39,958 shares of the company’s stock after buying an additional 31,331 shares during the period. Barclays PLC’s holdings in FibroBiologics were worth $123,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in FBLG. Charles Schwab Investment Management Inc. increased its position in FibroBiologics by 5.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 69,732 shares of the company’s stock worth $215,000 after buying an additional 3,451 shares during the period. The Manufacturers Life Insurance Company bought a new position in shares of FibroBiologics during the third quarter worth about $32,000. Mercer Global Advisors Inc. ADV acquired a new stake in shares of FibroBiologics in the 2nd quarter worth about $51,000. Jane Street Group LLC bought a new stake in FibroBiologics in the 3rd quarter valued at about $37,000. Finally, Rhumbline Advisers acquired a new position in FibroBiologics during the 2nd quarter valued at about $115,000.

Analyst Ratings Changes

FBLG has been the topic of several analyst reports. D. Boral Capital restated a “buy” rating and issued a $16.00 price target on shares of FibroBiologics in a research note on Friday, December 27th. Rodman & Renshaw began coverage on FibroBiologics in a research report on Thursday, December 12th. They issued a “buy” rating and a $12.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of FibroBiologics in a research report on Wednesday, November 13th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, FibroBiologics has an average rating of “Buy” and a consensus price target of $13.00.

FibroBiologics Stock Down 5.3 %

Shares of NASDAQ:FBLG opened at $1.60 on Friday. The company has a 50 day moving average of $2.25 and a 200-day moving average of $2.83. FibroBiologics, Inc. has a twelve month low of $1.08 and a twelve month high of $55.00.

About FibroBiologics

FibroBiologics, Inc operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.